Lonza Group AG

Price Chart

Risk-Adjusted Performance

Also Listed On

Lonza Group AG (LONN) Price Performance

Lonza Group AG (LONN) trades on SIX Swiss Exchange in CHF. The company is classified in the Healthcare sector under the Diagnostics & Research industry. The stock currently trades at CHF526.00, down 3.20% from the previous close.

Over the past year, LONN has traded between a low of CHF469.00 and a high of CHF596.39. The stock has lost 0.5% over this period. It is currently 8.9% below its 52-week high.

Lonza Group AG has a market capitalization of $35.97B, with a price-to-earnings ratio of 39.68 and a dividend yield of 0.99%.

About Lonza Group AG

Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.